Healing, surviving, or dying? - projecting the German future disease burden using a Markov illness-death model.
Chronic diseases
Compression of morbidity
Demography
Markov illness-death model
Projection
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
received:
13
07
2020
accepted:
19
11
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
In view of the upcoming demographic transition, there is still no clear evidence on how increasing life expectancy will affect future disease burden, especially regarding specific diseases. In our study, we project the future development of Germany's ten most common non-infectious diseases (arthrosis, coronary heart disease, pulmonary, bronchial and tracheal cancer, chronic obstructive pulmonary disease, cerebrovascular diseases, dementia, depression, diabetes, dorsal pain and heart failure) in a Markov illness-death model with recovery until 2060. The disease-specific input data stem from a consistent data set of a major sickness fund covering about four million people, the demographic components from official population statistics. Using six different scenarios concerning an expansion and a compression of morbidity as well as increasing recovery and effective prevention, we can show the possible future range of disease burden and, by disentangling the effects, reveal the significant differences between the various diseases in interaction with the demographic components. Our results indicate that, although strongly age-related diseases like dementia or heart failure show the highest relative increase rates, diseases of the musculoskeletal system, such as dorsal pain and arthrosis, still will be responsible for the majority of the German population's future disease burden in 2060, with about 25-27 and 13-15 million patients, respectively. Most importantly, for almost all considered diseases a significant increase in burden of disease can be expected even in case of a compression of morbidity. A massive case-load is emerging on the German health care system, which can only be alleviated by more effective prevention. Immediate action by policy makers and health care managers is needed, as otherwise the prevalence of widespread diseases will become unsustainable from a capacity point-of-view.
Sections du résumé
BACKGROUND
In view of the upcoming demographic transition, there is still no clear evidence on how increasing life expectancy will affect future disease burden, especially regarding specific diseases. In our study, we project the future development of Germany's ten most common non-infectious diseases (arthrosis, coronary heart disease, pulmonary, bronchial and tracheal cancer, chronic obstructive pulmonary disease, cerebrovascular diseases, dementia, depression, diabetes, dorsal pain and heart failure) in a Markov illness-death model with recovery until 2060.
METHODS
The disease-specific input data stem from a consistent data set of a major sickness fund covering about four million people, the demographic components from official population statistics. Using six different scenarios concerning an expansion and a compression of morbidity as well as increasing recovery and effective prevention, we can show the possible future range of disease burden and, by disentangling the effects, reveal the significant differences between the various diseases in interaction with the demographic components.
RESULTS
Our results indicate that, although strongly age-related diseases like dementia or heart failure show the highest relative increase rates, diseases of the musculoskeletal system, such as dorsal pain and arthrosis, still will be responsible for the majority of the German population's future disease burden in 2060, with about 25-27 and 13-15 million patients, respectively. Most importantly, for almost all considered diseases a significant increase in burden of disease can be expected even in case of a compression of morbidity.
CONCLUSION
A massive case-load is emerging on the German health care system, which can only be alleviated by more effective prevention. Immediate action by policy makers and health care managers is needed, as otherwise the prevalence of widespread diseases will become unsustainable from a capacity point-of-view.
Identifiants
pubmed: 33430836
doi: 10.1186/s12889-020-09941-6
pii: 10.1186/s12889-020-09941-6
pmc: PMC7799167
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Références
Lancet. 2015 Feb 7;385(9967):563-75
pubmed: 25468158
Theor Popul Biol. 2014 Mar;92:62-8
pubmed: 24333220
Hum Biol. 1951 Sep;23(3):205-41
pubmed: 14880165
Milbank Mem Fund Q Health Soc. 1984 Spring;62(2):143-66
pubmed: 6425716
PLoS One. 2015 Nov 30;10(11):e0143084
pubmed: 26619340
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Mar;56(3):447-54
pubmed: 23334292
N Engl J Med. 1980 Jul 17;303(3):130-5
pubmed: 7383070
BMC Geriatr. 2016 Feb 10;16:41
pubmed: 26864215
Psychother Psychosom Med Psychol. 2015 Dec;65(12):476-85; quiz 485
pubmed: 26623555
Diabet Med. 2019 Oct;36(10):1217-1225
pubmed: 30659656
Eur J Epidemiol. 2019 Nov;34(11):1075-1083
pubmed: 31612352
Eur J Epidemiol. 2005;20(10):827-32
pubmed: 16283472
J Health Econ. 2004 Mar;23(2):217-35
pubmed: 15019753
Med Care. 1984 Jun;22(6):511-26
pubmed: 6738142
Milbank Mem Fund Q Health Soc. 1984 Summer;62(3):475-519
pubmed: 6566016
Age Ageing. 2018 May 01;47(3):374-380
pubmed: 29370339
Semin Arthritis Rheum. 2016 Oct;46(2):160-167
pubmed: 27179749
Gesundheitswesen. 2016 Oct;78(10):e53-e58
pubmed: 26551850
Health Econ. 1999 Sep;8(6):485-96
pubmed: 10544314
Eur J Epidemiol. 2012 Oct;27(10):791-7
pubmed: 22878939
J Epidemiol Community Health. 2016 Oct;70(10):1011-6
pubmed: 27103663
Milbank Mem Fund Q Health Soc. 1977 Winter;55(1):3-24
pubmed: 141009
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Aug;62(8):993-1003
pubmed: 31243489
Am J Public Health. 1998 Sep;88(9):1337-42
pubmed: 9736873
Eur J Health Econ. 2020 Jun 4;:
pubmed: 32500244